- Home
- AMBC vs RIGL Comparison
AMBC vs RIGL Comparison
Compare AMBC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- RIGL
- Stock Information
- Founded
- AMBC 1971
- RIGL 1996
- Country
- AMBC United States
- RIGL United States
- Employees
- AMBC N/A
- RIGL N/A
- Industry
- AMBC Property-Casualty Insurers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- RIGL Health Care
- Exchange
- AMBC Nasdaq
- RIGL Nasdaq
- Market Cap
- AMBC 411.3M
- RIGL 335.5M
- IPO Year
- AMBC 1991
- RIGL 2000
- Fundamental
- Price
- AMBC $8.92
- RIGL $37.96
- Analyst Decision
- AMBC Strong Buy
- RIGL Buy
- Analyst Count
- AMBC 2
- RIGL 5
- Target Price
- AMBC $12.50
- RIGL $38.20
- AVG Volume (30 Days)
- AMBC 594.9K
- RIGL 761.5K
- Earning Date
- AMBC 11-11-2025
- RIGL 11-06-2025
- Dividend Yield
- AMBC N/A
- RIGL N/A
- EPS Growth
- AMBC N/A
- RIGL N/A
- EPS
- AMBC N/A
- RIGL 5.43
- Revenue
- AMBC $257,879,000.00
- RIGL $267,921,000.00
- Revenue This Year
- AMBC N/A
- RIGL $59.93
- Revenue Next Year
- AMBC $19.44
- RIGL N/A
- P/E Ratio
- AMBC N/A
- RIGL $6.99
- Revenue Growth
- AMBC 148.44
- RIGL 105.62
- 52 Week Low
- AMBC $5.99
- RIGL $12.76
- 52 Week High
- AMBC $13.64
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- AMBC 56.57
- RIGL 56.17
- Support Level
- AMBC $8.69
- RIGL $35.56
- Resistance Level
- AMBC $9.28
- RIGL $42.65
- Average True Range (ATR)
- AMBC 0.29
- RIGL 2.19
- MACD
- AMBC -0.02
- RIGL -1.00
- Stochastic Oscillator
- AMBC 45.57
- RIGL 32.70
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.